SCHEMBL509008

SCHEMBL509008

Cc1n[nH]c(CNCc2ccc(F)cc2)c1Oc1cc(Cl)cc(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
OXTR P30559 1/20 0.38
AVPR1A P37288 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KCNH2 Q12809 1/20 0.35
SCN8A Q9UQD0 1/20 0.34
HSD17B10 Q99714 1/20 0.34
P2RX7 Q99572 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
MAP2K4 P45985 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225076 0.90 KCNH2 (0.51) LMNAOXTRAVPR1AMEN1KMT2A
SCHEMBL509432 0.89 BCHE (0.40) LMNASCN8ASMN1; SMN2MAPT
SCHEMBL508181 0.86 KCNH2 (0.47) LMNAKCNH2SCN8AHSD17B10P2RX7
SCHEMBL5229533 0.84 P2RX7 (0.50) LMNAMEN1KMT2AP2RX7SMN1; SMN2
SCHEMBL5228111 0.82 KCNH2 (0.53) LMNAKCNH2HSD17B10P2RX7MAPT
SCHEMBL508578 0.82 KCNH2 (0.53) LMNAKCNH2SCN8ASMN1; SMN2
SCHEMBL509451 0.81 CYP1A2 (0.45) LMNAMEN1KMT2ASCN8AMAPT
SCHEMBL5228148 0.81 KCNH2 (0.53) LMNAKCNH2SCN8AHSD17B10P2RX7
SCHEMBL5226919 0.79 KCNH2 (0.51) LMNAKCNH2MAPT
SCHEMBL5226456 0.79 KCNH2 (0.48) KCNH2SCN8AP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377556-B1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LTD (GB) 2007-04-04 EP claimed
EP-1762567-A1 Pyrazole derivatives for treating HIV Pfizer Limited (GB) 2007-03-14 EP claimed
US-20030100554-A1 Pyrazole derivatives JONES LYN HOWARD (GB) 2003-05-29 US claimed
EP-1762567-B1 Pyrazole derivatives for treating HIV PFIZER LTD (GB) 2012-05-02 EP disclosed
US-20120029192-A1 Pyrazole Derivatives PFIZER INC 2012-02-02 US disclosed
US-8063044-B2 Pyrazole derivatives PFIZER INC. (US) 2011-11-22 US disclosed
US-8063044-B2 Pyrazole derivatives PFIZER INC. (US) 2011-11-22 US disclosed
US-8063044-B2 Pyrazole derivatives PFIZER INC. (US) 2011-11-22 US disclosed
US-20090215712-A1 PYRAZOLE DERIVATIVES PFIZER INC 2009-08-27 US disclosed
US-20090215712-A1 PYRAZOLE DERIVATIVES PFIZER INC 2009-08-27 US disclosed
US-20090215712-A1 PYRAZOLE DERIVATIVES PFIZER INC 2009-08-27 US disclosed
US-7435728-B2 Pyrazole derivatives PFIZER INC (US) 2008-10-14 US disclosed
US-7435728-B2 Pyrazole derivatives PFIZER INC (US) 2008-10-14 US disclosed
US-7435728-B2 Pyrazole derivatives PFIZER INC (US) 2008-10-14 US disclosed
EP-1377556-B1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LTD (GB) 2007-04-04 EP disclosed
EP-1377556-B1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LTD (GB) 2007-04-04 EP disclosed
EP-1762567-A1 Pyrazole derivatives for treating HIV Pfizer Limited (GB) 2007-03-14 EP disclosed
US-7109228-B2 Pyrazole derivatives AGOURON PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
US-20060020012-A1 Pyrazole derivatives PFIZER INC 2006-01-26 US disclosed
US-20030100554-A1 Pyrazole derivatives JONES LYN HOWARD (GB) 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215712-A1 PYRAZOLE DERIVATIVES RRM2B, REV1, RRM2 LMNA 3796/4885OXTR 3306/4885AVPR1A 1670/4885
US-20060020012-A1 Pyrazole derivatives PDCD11, RTF1, REV1 LMNA 3981/4885OXTR 2987/4885AVPR1A 1715/4885
US-20120029192-A1 Pyrazole Derivatives POLRMT, PDCD11, DPYD LMNA 3976/4885OXTR 3763/4885AVPR1A 2773/4885
US-20030100554-A1 Pyrazole derivatives REV1, SARS1, CYP2F1 LMNA 3857/4885OXTR 3999/4885AVPR1A 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.